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Abstract
Background: Infliximab is an anti-TNF alpha blocker frequently utilized in the management of
moderate to severe Crohn's Disease. The immunosuppressive effects of infliximab may increase the
risk for post-operative complications among Crohn's Disease patients undergoing abdominal surgery.
We conducted a systematic review andmeta-analysis of studies comparing the rates of post-operative
complications among Crohn's disease patients treated with Infliximab therapy versus alternative
therapies.
Methods: We used the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and searched 4 electronic databases along with major conference
abstract databases from inception of database until November, 2012. English-language
articles and abstracts evaluating post-operative complications among Crohn's disease
patients were considered eligible. We applied meta-analysis with random effects model to
calculate the overall odds ratio for total major complications as well as several secondary
outcomes.
Results: Data were extracted from six studies including 1159 patients among whom 413
complications were identified. The most common complications were wound infections,
anastomotic leak and sepsis. There was no significant difference in the major complication
rate (OR=1.59[95% C.I.: 0.89–2.86]; p=0.15), minor complication rate (OR=1.80 [C.I.:
0.87–3.71]; p=0.11), reoperation rate (OR=1.33 [C.I.: 0.55–3.20]; p=0.52) or 30 day mortality
rate (OR=3.74 [C.I.: 0.56–25.16]; p=0.13) between the Infliximab and control groups.tive Disease Week: Poster, San Diego California, May 2011. Canadian Digestive Disease Week: Poster,
90 Hornby Street, Vancouver, BC, Canada V6Z 2K5. Tel.: +1 604 688 6332; fax: +1 604 689 2004.
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869Infliximab and Post-Operative ComplicationsConclusions: This meta analysis provides some evidence that infliximab may be safe to continue
in the pre-operative period without increasing the risk of post-operative complications for
Crohn's disease patients undergoing abdominal surgery.
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Despite the advances in themedical therapy for Crohn's disease,
as many as 75% of patients eventually require surgery for the
management of their disease.1 Currentmedical management of
Crohn's Disease often utilizes one of the anti-TNF alpha
antibodies such as Infliximab, particularly for patients with
moderate to severe disease who have not responded to
other therapies.2,3 The use of anti TNF alpha therapies have
increased over time, however the rate of small bowel resection,
has remained constant.4 While these agents are effective at
inducing and maintaining remission,5 their immunosuppressive
effects may place patients at an increased risk of infection.6
There has been concern that the use of biologic agents in the
perioperative period would put these patients at a higher risk
for complications in general and infectious complications in
particular.
Several studies have observed the complication rates
amongst patients with CD undergoing surgery for treatment of
CD while having recently received or concurrently receiving
biologic drugs.7–12 All of the reports have been observational
studies or cohort studies and there are no reported random-
ized controlled studies. Most of these studies have not shown
an increased risk of post operative complications associated
with the pre-operative use of infliximab. However, this result
may be due to the small sample size of these studies and
therefore, the lack of a sufficient sample size to demonstrate
an association between infliximab exposure and post opera-
tive complications. A pooled estimate of the odds ratios from
studies examining pre-operative infliximab use and post-
operative complications may have sufficient power to detect
a previously unrecognized association. The objective of this
study was to firstly conduct a systematic review on this topic
and then to perform a meta-analysis of studies reporting onthe complication rates of Infliximab use in the pre-operative
period.2. Methods
2.1. Search strategy and study selection
A medical literature search was conducted using MEDLINE
(1948 to October, 2012), EMBASE (1980 to October, 2012), the
Cochrane central register of controlled trials (second quarter,
2012), the Cochrane database of systematic reviews (2005 to
October 2012) and Biosis Previews (1969 to October 2012). The
abstract books from major conference proceedings (2005
to 2012 for Digestive Disease Week, American College of
Gastroenterology and United European Gastroenterology
week) were searched to identify potentially eligible studies
only published in abstract form.
All trials examining postoperative complications in Crohn's
Disease patients undergoing surgery while using Infliximab
perioperatively were eligible for inclusion. Studies reporting
on any dose of Infliximab were eligible provided that the
medication was given within 90 days of surgery. Studies in
pediatric populations were excluded. Only those papers
reporting on postoperative complications occurring within
90 days were eligible. Papers had to be written in English to
be eligible and case studies or series were excluded. Review
articles and those studies reporting only on ulcerative colitis or
indeterminate bowel disease were also excluded.
Our search strategy utilized the terms Crohn's disease,
inflammatory bowel disease, regional enteritis and the
exploded term ileitis to identify papers on CD. The exploded
terms perioperative period and postoperative complications
and the floating subheading surgery were used to identify
870 G. Rosenfeld et al.papers relating to surgical complications. The terms infliximab,
Remicade and the exploded term antibodies, monoclonal were
used to identify those papers pertaining to the use of anti-TNF
alpha antibodies. The three sets of terms were then combined
using the set operator AND.
The papers identified by the initial search were evaluated
by the lead investigator (GR) for appropriateness to the study
question and all potentially relevant papers were obtained and
evaluated in detail. The bibliographies of all identified relevant
studies were used to perform a recursive search of the
literature. Experts in the field were contacted to try to identify
other unpublished studies. Where necessary, first or last
authors were contacted for additional information or clarifica-
tion of written information. Articles were assessed indepen-
dently by two investigators (GR and BB) using a pre-defined
protocol, according to the pre-defined eligibility criteria. Any
disagreement between investigators was resolved by discussion
between the investigators.
2.2. Outcome assessment
The primary outcome assessed was a comparison of the
complication rates between patients undergoing abdominal
surgery for treatment of Crohn's Disease who had also received
preoperative infliximab therapy and thosewhohad not received
preoperative infliximab. The complications were grouped into
major and minor complications for the purposes of data
analysis. Major complications included sepsis, anastomotic
leak, peritonitis, local fistula or abscess, wound infection,
wound failure, stoma complications, bowel perforation,
severe anemia and hemorrhage. Minor complications
included hematoma, fever, delayed transit, intestinal sub-
obstruction, minor wound infection, urinary tract infection
or other minor infections, and prolonged post-operative
ileus. Repeat operation rates as well as mortality rates at
30 days post-operatively were also assessed.
2.3. Data extraction
All data were extracted independently by the lead investigator
(GR) and entered into a Microsoft Excel spreadsheet (Excel for
Mac 2008 edition; Microsoft Corp, Redmond, WA, USA) as total
numbers of patients incurring each complication with the data
being verified by the other investigator (BB). In addition, the
following clinical data were extracted for each trial, where
available: demographic data of trial participants (age, and
gender), country of origin, geographical region, duration of
infliximab use both pre and post operatively, duration of follow
up, the type of surgery performed and concomitant medica-
tion use. The timing of the occurrence of complications was
recorded as occurring either early (within 30 days postoper-
atively) or late (between 30 and 90 days postoperatively). The
data were then pooled into major and minor complications as
defined above.
2.4. Statistical analysis
From the extracted data, the odds ratio and its 95% confidence
interval were estimated for each study. Where zero events
were reported for a given complication a treatment arm
continuity correctionmethodwas applied in the calculation.13It has been shown that treatment arm continuity correction
method outperformed the constant correction.13 Cochran's Q
test was used to evaluate heterogeneity across studies. The
quantity I2 was also calculated to describe the variation due to
heterogeneity rather than to chance between studies.14 We
applied a random effects model (Dersimonian and Laird
method) to calculate the overall odds ratio and its 95%
confidence interval for the complications studied. A Forest
plot was generated to visualize the heterogeneity among the
studies and show the overall odds ratio with 95% confidence
interval. Publication Bias was assessed using funnel plots along
with Begg's test and the Egger test to assess funnel plot
asymmetry. Sensitivity analyses were performed to examine
the influence of single study to the estimate of overall odds
ratio for the outcomes of major and minor complications. In
particular, the leave-one-out method was applied by exclud-
ing each study, one at a time and estimating overall odds ratio
with remaining studies. A similar sensitivity analysis was
conducted to determine the impact of excluding the data from
articles only published in abstract form. The analyses were
conducted using SAS (version 9.2) and R (version 2.12).3. Results
3.1. Search results
The search strategy employed identified 878 unique papers, 845
of which were excluded after examining the title and abstract
(Figure 1). A total of 33 observational studies reporting on the
complications of surgery in patients receiving infliximab in the
perioperative period, were retrieved for detailed evaluation.
After detailed review, 16 papers were excluded for various
reasons, including studies evaluating post-operative recurrence
of CD and not complications, studies including only patients
with ulcerative colitis and studies not specifically evaluating the
effect of anti-TNF alpha antibodies. A further 9 studies were
excluded from the final analysis because they only evaluated
peri-anal surgeries, they lacked a control group or they did
not distinguish the complications amongst patients taking
infliximab from those with other immunosuppressive therapies.
Kunitake et al.9 and Waterman et al.12 published studies on the
post-operative complications occurring in patients with inflam-
matory bowel disease being treated with infliximab prior to
surgery.Wewere not able to separate out the complication rate
amongst only the CD patients from those with ulcerative or
indeterminate colitis and therefore, these two studies had to be
excluded. Three additional studies,11,15,16 included patients on
different anti-TNF alpha antibodies and it was not possible to
determine the complications occurring specifically in those
patients on infliximab. All of the 8 remaining studies included
major complication rates, 5 included minor complication rates
and 3 included both repeat operation rates and 30-daymortality
data. The majority of the studies were performed in the United
States andwere retrospective studies with a case control design
(Table 1). Two of the studies were only presented in abstract
form and although they provided sufficient data in the abstract
(and authors provided supplementary data), they were exclud-
ed from the final analysis because they were never published as
manuscripts.17,18 This left 6 papers for inclusion in the final
analysis7,10,19–22 (Figure 1).
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There were a total of 1159 patients (257 in the Infliximab
group and 872 in the control group) in the six studies reporting
major complications in CD patients receiving Infliximab
preoperatively. In total, there were 99 complications in the
Infliximab group and 223 complications in the control group
providing a pooled odds ratio (OR) of 1.59 (95% CI 0.89–2.86;
p=0.15). The p-value of testing of heterogeneity was 0.011,
with I-square as 66.3% (Figure 2a). There was no significant
difference in the rate of major post-operative complications
in the infliximab treated group compared to the control group.
There was significant heterogeneity amongst the studies.
The sensitivity analysis shows that leaving out any one of the
included studies would not significantly impact the results
(Table 2). The most potentially influential study was the one
conducted by Appau et al. Excluding this study resulted in aFlowchart of Studie
889 Papers identified thro
database searching 
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n
878 Papers after duplicates r
878 Potential studies 
identified from database
records screened 
33 Full-text articles and
abstracts retrieved and 
assessed for eligibility 
17 Papers included in 
qualitative synthesis 
8 Studies included in 
quantitative synthesis 
(meta-analysis) 
Figure 1 Flowchdecrease in the effect of treatment on the occurrence of major
complications (pooled OR=1.17 with 95% CI of 0.80 to 1.73, p=
0.42). A further sensitivity analysis showed that whether or not
the data published in abstract form was included did not alter
the outcome formajor complications (pooledOR=1.69with 95%
CI of 0.83–3.43). A funnel plot (Figure 2b) was generated to
visually inspect for reporting bias and there was no evidence of
a significant publication bias as assessedwith the Begg's test (p=
0.45) and Egger test (p=0.22). However, given the small
number of studies included, there is low power to detect bias.3.3. Minor complications
Therewere a total of 564 patients observed in the three studies
reporting minor complications with 148 in the infliximab group
and 416 in the control group. 25 minor complications occurreds 
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emoved
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Table 1 The study characteristics for each of the included studies is shown in the above table. The number of subjects and the complication rates for each of the analyzed
variables is shown.
Study ID Journal Country Time period Study design Age range of
subjects INFLX
Duration of infliximab
exposure
Appau, et al. GI Surgery 2008 USA 1998–2007 Cohort 35.83+/−14.37
Bafford, et al. ACG 2010 Abstract USA 1999–2010 Retrospecti ve chart review 90 days prior to OR
Colombel, et al. Am J Gastro, 2004 USA 10/1998–12/01 Retrospecti ve chart review 40 range (12-83) 8 weeks before to
4 weeks post
Kasparek, et. al IBD 2011 Munich, Germany 01/2001–12/2008 Case control 35 (17–66) b3 months
Marchal, et al. Ali Pharm
Ther 2004
Belgium 12/1998–12/2002 Control cohort 36 (16–73) 31b=12 wks
9N=12 wks
Brzezinski, et al. Abstract DDW 2002 USA 2002 Case control
Tay et al. TTSurgery 2003 USA 1998–2002 Case control
Canedo et al. Colorectal Disease, 2010 USA 2000–2008 Retrospect ive cohort 26–52 3 months prior to OR
Subjects INFLX Controls (NON_INFLX) Total major complication Total minor Complication Re-operation 30 day mortality
Inflx Non-Inflx Inflx Non-Inflx Inflx Non-Inflx Inflx
60 329 42 111 1 1 5 10 1
35 161 7 28
52 218 12 51
48 48 16 15 17 9 11 10 1
40 39 12 8 7 7
22 61 7 16 7 23
22 78 3 8
65 160 14 30 2 9 0
872
G
.
Rosenfeld
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Figure 2 a: Forrest plot for major complications. b: Funnel plot for major complications.
873Infliximab and Post-Operative Complicationsin the infliximab group and 17 in the control group giving a
pooledOR for the two groups of 1.80 (95% CI 0.87–3.71; p=0.11)
(Figure 3a). There was no significant increase in the minor
complication rate for CD patients receiving infliximab prior to
surgery for their CD. The sensitivity analysis revealed that
leaving out any one of the studies did not alter the
conclusion (Table 3), nor did the decision to exclude the
abstract data. The testing for heterogeneity between the
studies was not significant with I2 =3.5% and p=0.3548
(Cochran's Q test). A funnel plot was generated and there
was no significant publication bias found using Begg's (p=1) and
Egger tests (p=0.65) (Figure 3b). However, there is limited
power to detect bias as only three studies were examined.3.4. Repeat operation and mortality rates
Three studies reported on both the need for a repeat operation
within 30 days and the 30-day mortality rate amongst patients
taking infliximab preoperatively who underwent surgery for
treatment of their CD.17 These studies included a total of 173
patients in the infliximab group and 537 in the control group.
There were 18 repeat operations reported for the infliximab
group and 29 for the control group. The pooled OR for the two
groups with respect to repeat operations was 1.33 (95% CI 0.55–
3.30; p=0.52)which is not statistically significant (Figure 4). For
30 day mortality, there were 2 mortalities in the infliximab
group and none in the control group. This difference was
not statistically different with a pooled OR of 3.74 (95% CI=
0.56–25.16; p=0.13) (Figure 5). There was no significantheterogeneity between the studies (I2=40.9%; p=0.1841 for
reoperation and I2=0%; p=0.7305 for 30 day mortality).4. Discussion
Our meta analysis shows that preoperative infliximab use
does not increase the risk of major postoperative compli-
cations for patients with Crohn's Disease undergoing intra-
abdominal surgery for management of their CD. The other
endpoints analyzed in this study also did not show a
statistically significant difference between the infliximab
treated and the control groups. The minor complication
rates were not increased for the infliximab groups in the 3
included studies. Three of the included studies7,20,22 looked
at the need for a repeat surgical procedure and again,
infliximab use in the pre-operative period did not increase
the need for repeat surgery. There were 2 mortalities
reported within the first 30 post-operative days both of
which occurred in the infliximab treated group.7 The low
number of events of these last two outcomes does not allow
us to make any conclusions regarding the association of
infliximab with the need for repeat surgery or postoperative
mortality.
The lack of an increase in the rate of major complications
was anticipated given that only one of the studies included
in our analysis found a statistically significant increase in
major postoperative complications.7 This study compared
three groups; those on perioperative infliximab, a control
group consisting of patients without exposure to infliximab
Table 2 Table showing the impact of excluding any one of the studies on the overall odds ration and 95% confidence interval for
major complications. (the “leave one out method”)
Excluded study Overall OR 95% CI (lower) 95% CI (upper) p-value
Appau, 2008 1.17 0.80 1.73 0.42
Colombel, 2004 1.78 0.92 3.44 0.09
Kasparek, 2011 1.71 0.87 3.38 0.12
Marchal, 2004 1.57 0.79 3.13 0.20
Tay, 2003 1.62 0.84 3.11 0.15
Canedo, 2011 1.69 0.83 3.43 0.14
All included studies 1.59 0.89 2.86 0.15
874 G. Rosenfeld et al.and patients with CD prior to the introduction of infliximab
in 1998 who were undergoing surgery. The inclusion of the
pre-infliximab group was intended to control for the
possibility that patients on infliximab may be sicker than
those not taking infliximab and therefore, they may be at an
increased risk of post-operative complications due to the
increased severity of their disease. When comparing the
three groups, there was a statistically significant increase in
the complications of sepsis and readmission rate amongst
the infliximab treated group versus the control and
pre-infliximab groups. As well, there were higher rates of
sepsis and intra-abdominal abscess for the infliximab group
over the pre-infliximab group suggesting that the severity of
disease may not be responsible for the higher infection rate.
An increased risk of post-operative infection would not be
surprising given that many of the patients were on concomitant
immunosuppressive medications which has been associated
with an increased risk of infection.23 For ulcerative colitis,
pre-operative infliximab use has been shown in a meta analysis
to increase the risk of short-term post-operative complications
where the riskwas attributed to an increased risk of infection.24
However, this association in ulcerative colitis is not as clear as itFigure 3 a: Forrest plot for minor complications. b: Funnel
plot for minor complications.might seem as other studies do not support this finding.25 For
Rheumatoid arthritis (RA), pre-operative infliximab use has also
been shown to be a risk factor for post-operative infections by
some. Giles et al.26 reviewed all of the RA patients who
attended the Johns Hopkins Arthritis Clinic between January 1,
1999 and March 15, 2004 and subsequently underwent
orthopedic surgery. Using univariate analysis, the prescription
of TNF inhibitor therapy was significantly associated with the
development of a serious post-operative infection (OR 4.4, 95%
CI 1.10–18.41). This association remained statistically signifi-
cant after adjustment for age, sex, and disease duration (OR
4.6, 95%CI 1.1–20.0); prednisone use, diabetes, and serum
rheumatoid factor status (OR 5.0, 95% CI 1.1–21.9); and all 6
variables simultaneously (OR 5.3, 95% CI 1.1–24.9).26
A large prospective study to evaluate the safety of CD
therapies, (the TREAT Registry) has found that infliximab use
alone is not a risk factor for serious infection.23 However,
corticosteroid use, narcotic use and moderate to severe
disease were independent risk factors for serious infection.
Pre-operative steroid use in patients with inflammatory bowel
disease undergoing abdominal surgery was the subject of a
prior meta analysis. In this study, the pooled OR for total
complications was 1.41 (95% CI 1.07–1.87) and for infectious
complications was 1.68 (95% CI 1.24–2.28).27 This study also
showed that the higher the dose of steroid, the greater the risk
of total complications (OR=2.04 95% CI 1.28–3.26). We were
unable to analyze the impact of concomitant medication use
as it was only recorded for three of the studies.7,10,21 One
study did look specifically at the impact of steroids as an
independent variable on rates of post-operative sepsis and did
not show pre-operative steroids to be a significant risk
factor.19 In a multivariable logistic regression analysis by
Appau et al., concomitant medications were not found to
significantly influence the major complication rate.7
A recent case-control retrospective study, looking at the
use of anti-TNF agents in the pre-operative period for
inflammatory bowel disease also did not find any significant
differences in the rate of post operative complications.12
Interestingly, there was a difference when the combined
endpoint of anastomotic leak, repeat operation and the
need for percutaneous drainage of an abscess were considered
(p=0.03). They also noted an increase in the rate of wound
infections for those on biologics in the univariate analysis (p=
0.008). However, this difference did not hold on multivariable
analysis. The authors also considered the timing of last
administration of biologic and the infliximab antibody levels
and again there was no difference in the complication rates
between those on pre-operative biologic therapy and those
who were not. This study had to be excluded from the present
Table 3 Table showing the impact of excluding any one of the included studies on the odds ration and 95% confidence interval
for minor complication rates.
Excluded study Overall OR 95% CI (lower) 95% CI (upper) p-value
Appau, 2008 1.27 0.62 2.58 0.51
Kasparek, 2011 0.98 0.46 2.05 0.95
Marchal, 2004 1.61 0.61 4.23 0.34
All studies included 1.80 0.87 3.71 0.11
875Infliximab and Post-Operative Complicationsanalysis because they considered all inflammatory bowel
disease together and did not distinguish surgeries in those with
Crohn's disease from those with Ulcerative colitis.
Our study has several limitations. Randomized controlled
trials are not possible in this study population as it would be
unethical to perform such trials given that infliximab is
frequently used to treat moderate to severe CD which is
refractory to other medical therapy.2 Therefore, our reported
estimates are based on lesser quality studies that have limited
control of bias. There was a high degree of heterogeneity in
the analyses of major complication rates. This is not
unexpected for observational studies and given the differ-
ences in the outcomes assessed by the included studies and
the potentially confounding variables. The 6 included
studies varied in terms of severity, location and duration
of disease, as well as the type of surgical procedure,
whether it looked at single or multiple surgical procedures
and the method (laparoscopic or open) of surgery. These
variables are not well addressed in the included studies and
therefore, could not be accounted for in this meta analysis.
Due to a lack of reported information, the influence of
concomitant immunosuppression use on our reported asso-
ciation is also not possible to appreciate. This is important
because immunosuppression could reasonably be expected
to increase the rate of post-operative infectious complica-
tions. We elected to exclude the two studies only reported
in abstract form in spite of direct communication with one
of the authors who provided additional information, in order
to limit any potential publication bias and because of a lack
of sufficient details regarding surgical procedures and
outcomes. Sensitivity analyses for major and minor compli-
cations showed that our decision to exclude these abstracts
did not significantly alter the outcome of the pooled OR.
Others have outlined the importance of a summary meta
analysis even in the setting of a high degree of heteroge-
neity.28 Our review further emphasizes that point because
examining the only study that reported a significantly
increased risk of post-operative major complications in
patients exposed to infliximab, might lead one to drawFigure 4 Forrest plot for re-operation rate.erroneous conclusions.7 This study was likely the main
contributor to the degree of heterogeneity for major
complications, while the remaining 5 studies included in
this analysis, produced more similar results. Some of the
heterogeneity may arise from the different outcomes of
the studies which were combined as major complications.
The pooled Odds Ratio allows for a more precise estimate of
the risk of pre-operative infliximab use, allowing clinicians
to gain a better understanding of this issue which is
important for patient care.
The results of this meta analysis are reassuring and help
to answer a very important clinical question. Infliximab and
other anti tumor necrosis factor alpha agents are being
used with increasing frequency in the management of
Crohn's disease. Consequently, many more patients are
coming to surgery having recently received one of these
immunosuppressive agents. This evidence provides some
support for clinicians who wish to counsel patients that the
pre-operative use of infliximab does not likely increase the
risk of post-operative complications and that infliximab
can be likely be safely continued or that surgery does not
need to be delayed because of the use of infliximab.
Nevertheless, some caution is warranted because although
there was no increased risk observed for infliximab, this is
not necessarily a class effect and it may not hold true for
other biologic drugs. Furthermore, the aforementioned
limitations of this study highlight the need for better
powered studies to draw definitive conclusions on the true
risk of infliximab use on post-operative complications.
In summary, in this meta-analysis, pre-operative infliximab
use was not shown to be associated with higher rates of major
post-operative complications in patients with Crohn's Disease
undergoing intra-abdominal surgery. Minor complications, the
need for a repeat operation and mortality within the first
30 days were also not affected by pre-operative infliximab
therapy. These results are somewhat reassuring that patients
who require surgery for management of their Crohn's Disease,
may be able to safely continue their infliximab therapy in the
pre-operative period.Figure 5 Forrest plot for 30-day mortality rate.
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